T. Zoto Et Al. , "Improved Anti-Emetic Efficacy of 5-HT3 Receptor Antagonists in Cancer Patients with Genetic Polymorphisms of ABCB1 (MDR1) Drug Transporter," BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY , vol.116, no.4, pp.354-360, 2015
Zoto, T. Et Al. 2015. Improved Anti-Emetic Efficacy of 5-HT3 Receptor Antagonists in Cancer Patients with Genetic Polymorphisms of ABCB1 (MDR1) Drug Transporter. BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY , vol.116, no.4 , 354-360.
Zoto, T., KILIÇKAP, S., YAŞAR, Ü., ÇELİK, İ., BOZKURT, A., & BABAOĞLU, M. Ö., (2015). Improved Anti-Emetic Efficacy of 5-HT3 Receptor Antagonists in Cancer Patients with Genetic Polymorphisms of ABCB1 (MDR1) Drug Transporter. BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY , vol.116, no.4, 354-360.
Zoto, Teuta Et Al. "Improved Anti-Emetic Efficacy of 5-HT3 Receptor Antagonists in Cancer Patients with Genetic Polymorphisms of ABCB1 (MDR1) Drug Transporter," BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY , vol.116, no.4, 354-360, 2015
Zoto, Teuta Et Al. "Improved Anti-Emetic Efficacy of 5-HT3 Receptor Antagonists in Cancer Patients with Genetic Polymorphisms of ABCB1 (MDR1) Drug Transporter." BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY , vol.116, no.4, pp.354-360, 2015
Zoto, T. Et Al. (2015) . "Improved Anti-Emetic Efficacy of 5-HT3 Receptor Antagonists in Cancer Patients with Genetic Polymorphisms of ABCB1 (MDR1) Drug Transporter." BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY , vol.116, no.4, pp.354-360.
@article{article, author={Teuta Zoto Et Al. }, title={Improved Anti-Emetic Efficacy of 5-HT3 Receptor Antagonists in Cancer Patients with Genetic Polymorphisms of ABCB1 (MDR1) Drug Transporter}, journal={BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY}, year=2015, pages={354-360} }